Please assess the completion status of the following clinical trial:

Trial Title: Food and Insulin Effect on QT/QTC Interval of ECG

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male or female, 20 - 45 years old~2. Signed ICF~3. Japanese - a descendant of four Japanese grandparents, carrying a Japanese passport and has not been outside Japan for more than 5 years prior to screening~4. The Caucasian - light to brown skin pigmentation; straight to wavy or curly hair; indigenous to Europe, northern Africa, western Asia, and India. The study may also include Caucasians from North America, Australia and South Africa~5. No clinical findings on the physical examination~6. Body mass index (BMI) = 18 - 25 kg/m2, body weight at least 48 kg.~7. Systolic blood pressure 90-145 mmHg, diastolic blood pressure 40-90 mmHg, and heart rate 40-90 bpm~8. Triplicate 12 lead ECG without clinically relevant abnormalities~9. 24 hour 12 lead Holter ECG without clinically relevant abnormalities~10. Haematology, biochemistry and urinalysis within the normal range~11. Must agree to use acceptable methods of contraception~Exclusion Criteria:~1. History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the study drug~2. History of clinically significant syncope.~3. Family history of sudden death.~4. Family history of premature cardiovascular death.~5. Family history of congenital long QT syndrome or Brugada's syndrome.~6. History of arrhythmias and ischemic heart disease~7. Conditions predisposing to electrolyte imbalances (e.g. altered nutritional states, chronic vomiting, anorexia nervosa, bulimia nervosa).~8. Abnormal ECG in the standard 12-lead ECG and 24-hour 12 lead Holter ECG~9. Abnormal rhythm, conduction or morphology of resting ECG, such as:~   * Sinus node dysfunction.~  * Clinically significant PR (PQ) interval prolongation.~  * Intermittent second or third degree AV block.~  * Incomplete or complete bundle branch block.~  * Abnormal T wave morphology.~  * Prolonged QTcB \>450 msec or shortened QTcB \< 350 msec or family history of long QT syndrome.~10. Abnormal blood glucose result (blood glucose \>7.8mmol/l)~11. Significant family history of diabetes mellitus.~12. Significantly elevated fasting blood glucose level~13. Signs and/or symptoms of acute illness in the four-week period prior to screening.~14. Veins unsuitable for intravenous puncture or cannulation on either arm~15. Known hypersensitivity to any medicines administered in the trial.~16. Treatment with any prescribed medication during the 2 weeks prior to first baseline day.~17. Treatment with any over-the-counter (OTC) medications during the 2 weeks prior to first baseline day.~18. Treatment with vitamins and/or minerals within 48 hours prior to the first baseline day.~19. Treatment with another investigational drug within 4 weeks prior to dosing or having participated in more than 3 investigational drug studies within a year prior to dosing.~20. Positive urine drug screen (amphetamines, benzodiazepines, cocaine, cannabinoids, opiates, barbiturates and methadone) or the alcohol breath test~21. History or clinical evidence of alcoholism (regular weekly alcohol intake of more than 14 units if female and 21 units if male) or drug abuse (compulsive, repetitive and/or chronic use of drugs or other substances with or without problems related to their use and/or where stopping or a reduction in dose will lead to withdrawal symptoms)~22. Excessive caffeine consumption (≥800 mg per day)~23. Smoking within 3 months prior to screening~24. Loss of 250 mL or more blood within 3 months prior to screening.~25. Positive results from the hepatitis serology, except for vaccinated subjects.~26. Positive results from the HIV serology.~27. Any circumstances or conditions, which may affect full participation in the study or compliance with the protocol.~28. Legal incapacity or limited legal capacity.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Moxifloxacin 400 mg fasted (Type: ACTIVE_COMPARATOR): Moxifloxacin 400 mg fasted was administered on Day 3. For Day 1 and 2, there were 4 different sequences: Placebo and Insulin Clamp; Insulin Clamp and Continental breakfast; Continental breakfast and FDA breakfast; FDA breakfast and Placebo. Additionally, Caucasian vs Japanese subjects were analysed.
- Moxifloxacin 400 mg fed (Type: EXPERIMENTAL): Moxifloxacin 400 mg fed was administered on Day 3 after Continental breakfast. For Day 1 and 2, there were 4 different sequences: Placebo and Insulin Clamp; Insulin Clamp and Continental breakfast; Continental breakfast and FDA breakfast; FDA breakfast and Placebo.~Additionally, Caucasian vs Japanese subjects were analysed.

Based on this trial design, predict the completion outcome and termination type (if applicable).